Vir Biotech, Wuxi Biologics End COVID-19 Antibody Collaboration | BioSpace

Retrieved on: 2022-05-24 02:36:27

Tags for this article:

Medical specialties

Medicine

COVID-19 drug development

Monoclonal antibodies

Coronavirus spike protein

SARS-CoV-2 Omicron variant

WuXi Biologics

COVID-19

Vir Biotechnology

Click the tags to see associated articles and topics

Vir Biotech, Wuxi Biologics End COVID-19 Antibody Collaboration | BioSpace. View article details on HISWAI: https://www.biospace.com/article/vir-biotechnology-and-wuxi-terminate-antibody-collaboration/

Excerpt

Vir Biotechnology terminated a two-year-old COVID-19-related antibody collaboration with Wuxi Biologics that included sotrovimab, which lost EUA ...

Article found on: www.biospace.com

View Original Article